HPS Pharmacies wish to give notice that all suppliers are experiencing a supply interruption for sulfamethoxazole + trimethoprim as follows:
(Sulfamethoxazole / trimethoprim)
|ARTG||Expected return date|
|Bactrim® Sugar-Free Oral Liquid||40mg/8mg/mL||119404||Discontinued|
|Septrin® Sugar-Free Oral Liquid||40mg/8mg/mL||11000||Mid-March 2019|
|Resprim® Tablets||400mg/80mg||17681||Currently available|
|Resprim® Forte Tablets||800mg/160mg||17682||Late February 2019|
|Septrim® Forte Tablets||800mg/160mg||10998||Mid-July 2019|
|Bactrim® DS Tablets||800mg/160mg||162563||Discontinued|
This supply interruption is due to an unexpected increase in demand following the discontinuation of the Bactrim® brand of sulfamethoxazole + trimethoprim tablets and oral liquid. An internationally registered brand of sulfamethoxazole + trimethoprim oral liquid has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that this alternative is subject to a longer lead time and different pricing as it must be sourced internationally. Additional care is also required as pertinent information is printed on the packaging in German. To ensure this product is used correctly, it must be shaken well before use, stored below 30°C, and discarded within 4 weeks of opening. For additional information, refer to the Australian product information and consumer medicines information for Septrin® Sugar-Free Oral Liquid.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.